Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 1148020210460010018
Á¶¼±´ëÇб³ÀÇ´ë³í¹®Áý
2021 Volume.46 No. 1 p.18 ~ p.20
Change of subtype in patients with advanced breast cancer after neoadjuvant chemotherapy
Kim Yoo-Seok

Kim Kweon-Cheon
Hong Ran
Abstract
Heterogeneity of breast cancer has been a challenge for treatment. Many studies have been conducted to improve the treatment outcome through identification of this heterogeneity. Among identified biologic makers, estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 have been used importantly as not only treatment target but also predicting prognosis. Nowadays, neoadjuvant chemotherapy is commonly used in patients with advanced breast cancer at diagnosis. Herein, we report the case in the which breast cancer subtype was changed after neoadjuvant chemotherapy.
KEYWORD
Biologic marker, Breast cancer, Estrogen receptor, Neoadjuvant chemotherapy
FullTexts / Linksout information
Listed journal information